Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

Journal of the American College of Cardiology

Volumn 56, Issue 20, 2010, Pages 1630-1636

  Bonello, Laurent ^a   Armero, Sébastien ^a   Mokhtar, Omar Ait ^a   Mancini, Julien ^b,c   Aldebert, Philippe ^a   Saut, Noémie ^d   Bonello, Nathalie ^b   Barragan, Paul ^e   Arques, Stéphane ^f   Giacomoni, Marie Paule ^g   Bonello Burignat, Caroline ^a   Bartholomei, Marie Noelle ^a   Dignat George, Françoise ^d,h   Camoin Jau, Laurence ^d,h   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSERM   (France)

^e Clinique les Fleurs   (France)

^f Centre Hospitalier d Aubagne   (France)

^g Service de Cardiologie   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Cytochrome 2C19 polymorphism; Percutaneous coronary intervention; Stent thrombosis; Vasodilator stimulated phosphoprotein

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; PROTON PUMP INHIBITOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; CELL ADHESION MOLECULE; CYP2C19 PROTEIN, HUMAN; DNA; DRUG DERIVATIVE; PHOSPHOPROTEIN; PLASMA PROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ALLELE; ARTICLE; FEMALE; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; WILD TYPE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FOLLOW UP; GENETICS; GENOTYPE; METHODOLOGY; MIDDLE AGED; MONITORING; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ALLELES; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; BLOOD PROTEINS; CELL ADHESION MOLECULES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHOSPHOPROTEINS; PLATELET ACTIVATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77958573028     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.004     Document Type: Article

References (29)

1. Gurbel PA, Bliden KP, Samara W, et al. The Clopidogrel Resistance and Stent Thrombosis (CREST) study. J Am Coll Cardiol 2005;46: 1827-32.
2. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
3. Buonamici P, Marcucci R, Miglironi A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-7. (Pubitemid 46891710)
4. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-6. (Pubitemid 47091403)
5. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329 -34. (Pubitemid 350239106)
6. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838-43. (Pubitemid 47555077)
7. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34. (Pubitemid 350007957)
8. Morel O, Viellard C, Faure A, et al. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intra-platelet VASP phosphorylation.] Ann Cardiol Angeiol Paris 2007;56:21-9. (Pubitemid 46037642)
9. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol 2010. In press.
10. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244 -7. (Pubitemid 44497506)
11. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309 -17.
12. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
13. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849 -57.
14. Simon T, Verstuyft C, Mary-Krause M, et al., French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360: 363-75.
15. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404 -11. (Pubitemid 351447314)
16. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
17. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009;37:2145-52.
18. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9.
19. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288 -95. (Pubitemid 35265838)
20. Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:199S-233S. (Pubitemid 351894914)
21. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681-4. (Pubitemid 44233472)
22. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120: 2577-85.
23. Angiolillo DJ, Ferna'ndez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10. (Pubitemid 39452607)
24. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed March 24, 2010.
25. Angiolillo DJ, Ferna'ndez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose weight adjusted? J Invasive Cardiol 2004;16:169 -74. (Pubitemid 38456448)
26. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603.
27. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:1511-5.
28. Scherrer U, Nussberger J, Torriani S, et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation 1991;83: 552-8.
29. Kotlyar M, Carson SW. Effects of obesity on the cytochromes P450 enzyme system. Int J Pharmacol Ther 1999;37:8 -19. (Pubitemid 29043392)